Comparison of blood tests for liver fibrosis specific or not to NAFLD

Calès, Paul; Lainé, Fabrice; Boursier, Jérôme; Deugnier, Yves; Moal, Valérie; Oberti, Frédéric; Hunault, Gilles; Rousselet, Marie Christine; Hubert, I.; Laafi, Jihane; Ducluzeaux, Pierre Henri; Lunel, F.

doi:10.1016/j.jhep.2008.07.035

Cited by 226 publications

(171 citation statements)

References 44 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…119,120 It could not only distinguish NASH from simple nonprogressive steatosis but also indicate the severity of hepatic fibrosis in NASH. [121][122][123][124][125][126][127][128][129] High-sensitivity CRP, circulating TNF-a, interleukin-6 and cytokine-18 levels are significantly increased in NASH compared with simple steatosis and healthy volunteers. 111,122,123 Hypoadiponectinemia in NAFLD is part of a metabolic disturbance characterized by decreased hepatic insulin sensitivity and by increased ectopic fat accumulation in the central compartment, especially in the liver.…”

Section: Biomarkersmentioning

confidence: 99%

Nonalcoholic fatty liver disease: a challenge for pediatricians

Widhalm

Ghods

2010

Int J Obes

View full text Add to dashboard Cite

Background: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of pediatric liver disease. Its prevalence is related to the growing epidemic in childhood obesity during the past decades. At present, NAFLD and nonalcoholic steatohepatitis (NASH) are increasingly recognized worldwide. In spite of alarming trend in the epidemiology in pediatric field and growing risk of end stage liver disease, there is no significant advance in its diagnosis and treatment. Aim: To provide a detailed review for diagnosis and management of NAFLD and NASH. Methods: By using Pubmed to find review articles and relevant research. Results: The prevalence ranges from at least 3% in children overall to about 50% in obese children. The noninvasive biomarkers can be used to identify NAFLD/NASH patients. Diagnostic criteria based on biochemical and immunological indicators in the high-risk group of children could prevent about half of cases from receiving an invasive test. The pharmacological and surgical interventions have shown a growing role in pediatric NAFLD. Novel treatment modalities, such as probiotics, have hardly been studied. Conclusion: Early diagnosis by using noninvasive screening methods in high-risk groups is the most effective strategy against the NAFLD. The biology of early growth and development, including hepatic metabolism, may hold the key to pediatric NAFLD. Prevention of overweight children and childhood obesity is undoubtedly the best strategy for treating NAFLD.

show abstract

Section: Biomarkersmentioning

confidence: 99%

Nonalcoholic fatty liver disease: a challenge for pediatricians

Widhalm

Ghods

2010

Int J Obes

View full text Add to dashboard Cite

show abstract

“…Several models to predict the extent of fibrosis in NAFLD patients have been reported. [15][16][17] In general, most of these show similar accuracy for the detection of advanced fibrosis, but weak accuracy for that of mild fibrosis. This represents a limitation for the screening of patients with NAFLD.…”

Section: Editorialsmentioning

confidence: 99%

Will non‐invasive markers replace liver biopsy for diagnosing and staging fibrosis in non‐alcoholic steatohepatitis?

Hashimoto

Farrell

2009

J of Gastro and Hepatol

View full text Add to dashboard Cite

“…Bei einem direkten Vergleich zeigte sich Fibrometer ® beim Nachweis einer signifikanten Fibrose ( > F2) mit einer AUROC von 0,94 gegenüber dem von den amerikanischen Gastroenterologen favorisierten NAFLD-Fibrose Score (AUROC 0,88) und APRI (AUROC 0,87) überlegen. Bei der Diagnose der Zirrhose bestand kein Unterschied (AUROCs: 0,90, 0,90, 0,84) [34]. In einer anderen Vergleichsstudie [35] Zusammengefasst gibt es leider keinen einzelnen Laborparameter, der die Diagnosen oder Stadien-Einteilungen von NAFLD oder NASH sicher ermöglicht.…”

Section: Praxis-empfehlungen Zu Diagnostik Und Management Der Nafldunclassified

Labordiagnostik der Leberfibrose und der nichtalkoholischen Fettleber-Krankheit

Eckardstein

2014

LaboratoriumsMedizin

View full text Add to dashboard Cite

ZusammenfassungDurch ihre hohe Prävalenz und die assoziierten Folge-Erkrankungen sind Leberfibrose jeglicher Ätiologie sowie die nicht-alkoholische Fettlebererkrankung (NAFLD) wichtige öffentliche Gesundheitsprobleme. Die Leberbiopsie gilt als Goldstandard für die Diagnostik und die Stadieneinteilung der Leberfibrose und NAFLD. In den letzten Jahren wurden etliche auf Laborparameter und/oder Bildgebungsverfahren basierende nichtinvasive Verfahren für die Diagnostik von Leberfibrose bei chronischer Hepatitis und NAFLD entwickelt und validiert. Im Vergleich zu den patentierten Tests (FibroTest

show abstract

Comparison of blood tests for liver fibrosis specific or not to NAFLD

Cited by 226 publications

References 44 publications

Nonalcoholic fatty liver disease: a challenge for pediatricians

Nonalcoholic fatty liver disease: a challenge for pediatricians

Will non‐invasive markers replace liver biopsy for diagnosing and staging fibrosis in non‐alcoholic steatohepatitis?

Labordiagnostik der Leberfibrose und der nichtalkoholischen Fettleber-Krankheit

Contact Info

Product

Resources

About